128 related articles for article (PubMed ID: 12115071)
1. Chemotherapy did not enhance the anti-osteolytic effects of bisphosphonate in multiple myeloma bone disease.
Ogata A; Kitano M; Hashimoto N; Iwasaki T; Hamano T; Kakishita E
J Bone Miner Metab; 2002; 20(4):240-2. PubMed ID: 12115071
[No Abstract] [Full Text] [Related]
2. Biphasic anti-osteoclastic action of intravenous alendronate therapy in multiple myeloma bone disease.
Kitano M; Ogata A; Sekiguchi M; Hamano T; Sano H
J Bone Miner Metab; 2005; 23(1):48-52. PubMed ID: 15616894
[TBL] [Abstract][Full Text] [Related]
3. Myeloma bone disease: pathogenetic mechanisms and clinical assessment.
Silvestris F; Lombardi L; De Matteo M; Bruno A; Dammacco F
Leuk Res; 2007 Feb; 31(2):129-38. PubMed ID: 16764925
[TBL] [Abstract][Full Text] [Related]
4. [Effect of bisphosphonate on myeloma bone disease].
Abe M; Matsumoto T; Kosaka M
Rinsho Ketsueki; 2002 May; 43(5):349-52. PubMed ID: 12096484
[No Abstract] [Full Text] [Related]
5. Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis.
Sevcik MA; Luger NM; Mach DB; Sabino MA; Peters CM; Ghilardi JR; Schwei MJ; Röhrich H; De Felipe C; Kuskowski MA; Mantyh PW
Pain; 2004 Sep; 111(1-2):169-80. PubMed ID: 15327821
[TBL] [Abstract][Full Text] [Related]
6. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
[TBL] [Abstract][Full Text] [Related]
7. Dickkopf-1: a suitable target for the management of myeloma bone disease.
Gavriatopoulou M; Dimopoulos MA; Christoulas D; Migkou M; Iakovaki M; Gkotzamanidou M; Terpos E
Expert Opin Ther Targets; 2009 Jul; 13(7):839-48. PubMed ID: 19530987
[TBL] [Abstract][Full Text] [Related]
8. Use of clodronate in multiple myeloma.
Jantunen E; Lahtinen R; Laakso M
Leuk Lymphoma; 1995 Oct; 19(3-4):207-11. PubMed ID: 8535211
[TBL] [Abstract][Full Text] [Related]
9. [Neurologic sequelae of bone changes in multiple myeloma and its therapy].
Basić-kes V; Basić-Jukić N; Kes P; Demarin V; Labar B
Acta Med Croatica; 2002; 56(3):103-7. PubMed ID: 12630341
[TBL] [Abstract][Full Text] [Related]
10. Pathophysiology of multiple myeloma bone disease.
Lentzsch S; Ehrlich LA; Roodman GD
Hematol Oncol Clin North Am; 2007 Dec; 21(6):1035-49, viii. PubMed ID: 17996587
[TBL] [Abstract][Full Text] [Related]
11. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
Tosi P; Zamagni E; Cellini C; Parente R; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Boni P; Tura S; Baccarani M; Cavo M
Eur J Haematol; 2006 May; 76(5):399-404. PubMed ID: 16480429
[TBL] [Abstract][Full Text] [Related]
12. [Effects of pamidronate disodium (Bonin) combined with chemotherapy on bone pain in multiple myeloma].
Leng Y; Chen SL; Shi HZ
Space Med Med Eng (Beijing); 2002 Oct; 15(5):377-8. PubMed ID: 12449148
[TBL] [Abstract][Full Text] [Related]
13. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
[TBL] [Abstract][Full Text] [Related]
14. Bone markers in multiple myeloma.
Heider U; Fleissner C; Zavrski I; Kaiser M; Hecht M; Jakob C; Sezer O
Eur J Cancer; 2006 Jul; 42(11):1544-53. PubMed ID: 16765040
[TBL] [Abstract][Full Text] [Related]
15. [Multiple myeloma and bone manifestations. Role of clodronate].
Bauduer F; Delmer A
Bull Cancer; 1996 Jul; 83(7):542-7. PubMed ID: 8868941
[TBL] [Abstract][Full Text] [Related]
16. Effects of bortezomib on bone disease in multiple myeloma.
Drake MT; Rajkumar SV
Am J Hematol; 2009 Jan; 84(1):1-2. PubMed ID: 19030185
[No Abstract] [Full Text] [Related]
17. Treatment strategies for bone disease.
Roodman GD
Bone Marrow Transplant; 2007 Dec; 40(12):1139-46. PubMed ID: 17680018
[TBL] [Abstract][Full Text] [Related]
18. [Salmon calcitonin in supportive therapy of neoplastic osteolysis. Preliminary report on a case of myeloma].
Andriani A; Beni A; Beni RA; Calistri A; Gelli GF
Clin Ter; 1981 Jan; 96(2):183-91. PubMed ID: 7237953
[No Abstract] [Full Text] [Related]
19. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.
Heider U; Langelotz C; Jakob C; Zavrski I; Fleissner C; Eucker J; Possinger K; Hofbauer LC; Sezer O
Clin Cancer Res; 2003 Apr; 9(4):1436-40. PubMed ID: 12684416
[TBL] [Abstract][Full Text] [Related]
20. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
